Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | The role of HSCT in the treatment of relapsing-remitting and secondary progressive MS

Alice Mariottini, MD, University of Florence, Florence, Italy, discusses a study investigating long-term outcomes of hematopoietic stem cell transplantation (HSCT) in multiple sclerosis (MS) using an anti-thymocyte globulin (ATG)-based conditioning regimen. The study included 110 patients and reported a treatment-related mortality (TRM) of 0.9%. Viral reactivations requiring treatment occurred in 24% of patients. After a median follow-up of 5 years, the progression-free survival (PFS) and survival free from clinical or radiological activity were 69% and 68%, respectively. At 10 years, PFS was 100% in relapsing-remitting patients but only 27% in secondary progressive patients, highlighting the effectiveness of HSCT in relapsing-remitting MS and the need for further research to improve outcomes in secondary progressive MS. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.